Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide

Iris Maria Forte(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Antonio Giordano(University of Siena)
International Journal of Oncology
April 16, 2019
Cited by 42


Related Papers